Test2Learn

TARGET AUDIENCE

All healthcare professionals

---

EDUCATION MODULES

Self-paced, online study Precision medicine and PGx (2 units) Foundations of PGx (4 units) PGx testing (3 units) PGx decision making (6 units)  PGx in clinical practice (5 units) Keys to successful implementation (7 units)

Live session Variation: One size does not fit all Using of trustworthy online information  How does a lab assign diplotypes Phenotypes to recommendations Decision making in practice: working through complex cases Developing PGx patient care plans Advancing your successful implementation and Wrap Up

---

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

Foundational Genetics Concepts (FG)

Explain basic genetics concepts using appropriate nomenclature. Recognize the combined impact of genetic, behavioral, social, and environmental factors in the manifestation of disease and drug response. Identify drug- and disease-associated genetic variations that facilitate development of prevention, diagnostic, and treatment strategies. Differentiate between the clinical diagnosis of disease informed by genetics and the identification of genetic predisposition to disease. Assess differences in genetic testing technologies, including sequencing and genotyping. Recognize the legal protections against discrimination based on genetic test results.

Clinical PGx (CP)

Identify pharmacogenomic test results that are relevant to a patient’s care. Interpret pharmacogenomic test results, including translating genotype to phenotype to drug therapy recommendation.  Determine the impact of genetic variation on pharmacokinetics and/or pharmacodynamics.  Identify medication-related problems that may be related to genetic variability, even when a pharmacogenomic test has not been done. Recognize disease implications of pharmacogenomic test results and refer the patient to a genetics-trained healthcare provider when necessary. Use family history to assess predisposition to disease and drug response.  Assess the quality and source of existing pharmacogenomic test results. Distinguish between actionable and non-actionable pharmacogenomic test results using high-quality, evidence-based pharmacogenomics databases and clinical guidelines.  Integrate pharmacogenomic test results with other clinical variables to optimize medication therapy. Recommend pharmacogenomic testing when appropriate. Consider the cost, cost-effectiveness, and reimbursement issues relevant to pharmacogenomic tests and services. Implement a pharmacogenomics-guided care plan in collaboration with the patient, caregivers, and other health professionals. Document pharmacogenomic test results in the electronic health record. Follow-up and monitor a pharmacogenomics-guided care plan. Collaborate as a member of an interprofessional clinical pharmacogenomics team. Identify patient populations that may be most likely to benefit from pharmacogenomic testing.  Identify genetic variations that predispose patients to adverse drug reactions and modify therapy accordingly to mitigate the risk.  Recognize the differences in pharmacogenomic allele frequencies among ancestry groups to guide appropriate test selection and maximize the appropriate use of medications in a population. Educate patients and professional colleagues on the benefits and limitations of pharmacogenomics to optimize drug therapy. Use a culturally-sensitive approach that considers potential ethical concerns when counseling patients about pharmacogenomic test results.  Use evidence-based resources and pharmacogenomics information to advance patient care. Oversee clinical pharmacogenomics operations. Fulfill a medication order considering the clinical implications of pharmacogenomics. Create a written plan for continuous professional development in clinical pharmacogenomics.

---

DISCLAIMER STATEMENT

The information presented at this activity represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the UPMC Center for Continuing Education in the Health Sciences, UPMC / University of Pittsburgh Medical Center or Affiliates and University of Pittsburgh School of Medicine.  Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

PLANNING COMMITTEE

	Philip Empey, PharmD, PhD,  FCCP Associate Professor, Pharmacy and Therapeutics, Associate Director, Institute of Precision Medicine; University of Pittsburgh School of Pharmacy (Course Director)
	James Coons, PharmD, FCCP, FACC, BCCP Professor, Pharmacy and Therapeutics, PGY2 Cardiology Residency Program Director, University of Pittsburgh School of Pharmacy
	Lucas Berenbrok, PharmD, MS, BCACP, TTS Associate Professor, Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy
	Ashley Stewart, EdD, MA Instructional Designer, University of Pittsburgh School of Pharmacy
	Deepak Voora, MD  Executive Director, VA National Pharmacogenomics Program VA Central Office, Washington, DC
	Jill Bates PharmD, MS, BCOP, DipACLM, FASHP Deputy Executive Director, VA National Pharmacogenomics Program VA Central Office, Washington, DC
	Trina Walker, DNP, APRN, FNP-C Assistant Professor, Nursing Creighton University
	Nguyen Park, MS, PA-C President and Founder, Society of PAs in Genetics/Genomics

---

PRENSENTERS (ALPHABETICAL ORDER)

	Lucas Berenbrok, PharmD, MS, BCACP, TTS Associate Professor, Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy
	Kelly Caudle, PharmD, PhD, BCPS, FCCP Associate Member, St. Jude Children's Research Hospital CPIC Director
	James Coons, PharmD, FCCP, FACC, BCCP Professor, Pharmacy and Therapeutics, PGY2 Cardiology Residency Program Director, University of Pittsburgh School of Pharmacy
	Philip Empey, PharmD, PhD,  FCCP Associate Professor, Pharmacy and Therapeutics, Associate Director, Institute of Precision Medicine; University of Pittsburgh School of Pharmacy
	Mylynda Massart, MD, PhD Associate Professor, Department of Family Medicine Primary Care Precision Medicine University of Pittsburgh
	Lisa Parker, PhD Director, Center for Bioethics and Health Law University of Pittsburgh
	Katherine Robinson, PharmD, MS, BCPS Clinical Pharmacogenomics Pharmacist University of Pittsburgh School of Pharmacy
	Sara Rogers, PharmD Clinical Assistant Professor Texas A&M University
	Kayla Rowe, PharmD Clinical Pharmacogenomics Fellow University of Pittsburgh
	Robert Schuck, PharmD, PhD Deputy Director, Division of Translational and Precision Medicine Office of Clinical Pharmacology Center for Drug Evaluation and Research US Food and Drug Administration
	Todd Skaar, MS, PhD Professor, Clinical Pharmacology Indiana University School of Medicine
	James Stevenson, PharmD, MS Assistant Professor, Departments of Medicine and Pharmacology & Molecular Sciences Johns Hopkins University School of Medicine
	Emma Tillman, PharmD, PhD Associate Research Professor, Division of Clinical Pharmacology Indiana University School of Medicine
	Michelle Whirl-Carrillo, PhD Principal Investigator and Director, PharmGKB Department of Biomedical Data Science Stanford University

---

CONFLICT OF INTEREST

No members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients to disclose.

ACCREDITATION

In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME) and the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Pharmacy (CPE)

This knowledge-based activity provides 20.0 contact hours of continuing pharmacy education credit.

Physician (CME)

The University of Pittsburgh designates this live activity for a maximum of 20.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing (CNE)

The maximum number of hours awarded for this Continuing Nursing Education activity is 20.0 contact hours.

Physician Assistant (AAPA)

The University of Pittsburgh has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credits for activities planned in accordance with AAPA CME Criteria. This activity is designated for 20.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.  

Other healthcare professionals

Will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.

---

HOW TO OBTAIN CONTINUING EDUCATION

Continuing education can be claimed for the above learner groups. Learners must complete the full program (all modules, attain grades of 80% or higher on assessments, and participate in the live session) as well as submit the required information to the CE office (e.g. profile information and evaluations) prior to the deadline to receive continuing education credit. Partial credit will not be awarded.

Test2LearnTM is an award-winning training approach where you can work with real genetic data to learn pharmacogenomics. You can experience personal genomics testing just like your patients or work with anonymous data. Interactive exercises and real world cases increase the fidelity of education and make training fun. Learn all about our learning outcomes by clicking on the logo to the left.

TARGET AUDIENCE

This course is designed for all healthcare professionals, including nurses, nurse practitioners, pharmacists, physicians and physician assistants.

---

LEARNING MODULES

1. What is pharmacogenomics (PGx)
2. All about PGx testing
3. PGx clinical decision making
4. Putting PGx into practice (real-world implementation)

---

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

Define pharmacogenomics (PGx). Describe how genetic variation can impact medication outcomes. Recognize the availability of evidence-based guidelines to guide clinical decision making using PGx. Interpret PGx test results that may be relevant to a patient's care. Distinguish clinical situations when PGx testing is likely to have value for patients and populations. Describe the landscape of pharmacogenomics implementation.

PLANNING COMMITTEE

	Philip Empey, PharmD, PhD,  FCCP Associate Professor, Pharmacy and Therapeutics, Associate Director, Institute of Precision Medicine; University of Pittsburgh School of Pharmacy (Program Director)
	James Coons, PharmD, FCCP, FACC, BCCP Professor, Pharmacy and Therapeutics, PGY2 Cardiology Residency Program Director, University of Pittsburgh School of Pharmacy
	Lucas Berenbrok, PharmD, MS, BCACP, TTS Associate Professor, Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy
	Deepak Voora, MD  Executive Director, VA National Pharmacogenomics Program VA Central Office, Washington, DC
	Jill Bates PharmD, MS, BCOP, DipACLM, FASHP Deputy Executive Director, VA National Pharmacogenomics Program VA Central Office, Washington, DC
	Trina Walker, DNP, APRN, FNP-C Assistant Professor, Nursing Creighton University
	Nguyen Park, MS, PA-C President and Founder, Society of PAs in Genetics/Genomics

---

PRESENTER

Philip Empey, PharmD, PhD,  FCCP Associate Professor, Pharmacy and Therapeutics, Associate Director, Institute of Precision Medicine; University of Pittsburgh School of Pharmacy

---

CONFLICT OF INTEREST

Dr. Coons discloses that he receives grant/research support from Heart Rhythm Society, and Bristol Myers Squibb Alliance. He is a consultant for Merck, Bristol Myers Squibb, AstraZeneca and Johnson & Johnson.

No other planners, members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose.

ACCREDITATION

In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME) and the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Pharmacy (CPE)

This knowledge-based activity provides 1.0 contact hours of continuing pharmacy education credit.

Physician (CME)

The University of Pittsburgh designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing (CNE)

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours.

Physician Assistant (AAPA)

The University of Pittsburgh has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credits for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.  

Other healthcare professionals

Will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.

---

DISCLAIMER STATEMENT

The information presented at this activity represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the UPMC Center for Continuing Education in the Health Sciences, UPMC / University of Pittsburgh Medical Center or Affiliates and University of Pittsburgh School of Medicine.  Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

---

HOW TO OBTAIN CONTINUING EDUCATION

Continuing education can be claimed for the above learner groups. Learners must complete the full program (all modules, attain grades of 80% or higher on assessments, and participate in the live session) as well as submit the required information to the CE office (e.g. profile information and evaluations) prior to the deadline to receive continuing education credit. Partial credit will not be awarded.

Released: 2/14/2024
Expires: 9/30/2027

TARGET AUDIENCE

This course is designed for all healthcare professionals, including Nurses, Nurse Practitioners, Pharmacists, Physicians and Physician Assistants.

---

LEARNING MODULES

1. Precision medicine and PGx (2 units)
2. Foundations of PGx (3 units)
3. All about testing (3 units)
4. Principles of PGx decision making (5 units) 
5. Integrating PGx into your cardiology practice (3 units)
   

---

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

Review foundational genomic concepts and nomenclature. Describe how PGx variation affects the pharmacokinetics and pharmacodynamics of cardiovascular medications. Order quality PGx testing when appropriate for cardiology patients across their patient care journey. Explain the individual and societal risks and benefits of genetic testing in the healthcare setting. Identify gene-drug pairs and seminal clinical trial data with a high level of evidence in cardiology. Develop a stepwise decision-making process for the integration of PGx with clinical variables (e.g. phenoconversion) that known to impact PK/PD to make appropriate recommendations for cardiology patients and populations. Identify one's own role and that of other interprofessional team members to apply PGx into practice.

COURSE DURATION

Once enrolled, learners have 60 days to complete the program.

PLANNING COMMITTEE

	Philip Empey, PharmD, PhD,  FCCP Associate Professor, Pharmacy and Therapeutics, Associate Director, Institute of Precision Medicine; University of Pittsburgh School of Pharmacy (Course Director)
	James Coons, PharmD, FCCP, FACC, BCCP Professor, Pharmacy and Therapeutics, PGY2 Cardiology Residency Program Director, University of Pittsburgh School of Pharmacy
	Lucas Berenbrok, PharmD, MS, BCACP, TTS Associate Professor, Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy
	Deepak Voora, MD  Executive Director, VA National Pharmacogenomics Program VA Central Office, Washington, DC
	Jill Bates PharmD, MS, BCOP, DipACLM, FASHP Deputy Executive Director, VA National Pharmacogenomics Program VA Central Office, Washington, DC
	Trina Walker, DNP, APRN, FNP-C Assistant Professor, Nursing Creighton University
	Nguyen Park, MS, PA-C President and Founder, Society of PAs in Genetics/Genomics

---

PRENSENTERS (ALPHABETICAL ORDER)

	Lucas Berenbrok, PharmD, MS, BCACP, TTS Associate Professor, Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy
	Kelly Caudle, PharmD, PhD, BCPS, FCCP Associate Member, St. Jude Children's Research Hospital CPIC Director
	James Coons, PharmD, FCCP, FACC, BCCP Professor, Pharmacy and Therapeutics, PGY2 Cardiology Residency Program Director, University of Pittsburgh School of Pharmacy
	Philip Empey, PharmD, PhD,  FCCP Associate Professor, Pharmacy and Therapeutics, Associate Director, Institute of Precision Medicine; University of Pittsburgh School of Pharmacy
	Mylynda Massart, MD, PhD Associate Professor, Department of Family Medicine Primary Care Precision Medicine University of Pittsburgh
	Lisa Parker, PhD Director, Center for Bioethics and Health Law University of Pittsburgh
	Robert Schuck, PharmD, PhD Deputy Director, Division of Translational and Precision Medicine Office of Clinical Pharmacology Center for Drug Evaluation and Research US Food and Drug Administration
	Michelle Whirl-Carrillo, PhD Principal Investigator and Director, PharmGKB Department of Biomedical Data Science Stanford University

---

CONFLICT OF INTEREST

Dr. Coons discloses that he receives grant/research support from Heart Rhythm Society, and Pfizer-Bristol Myers Squibb Alliance. He is a consultant for Merck and Pfizer-Bristol Myers Squibb Alliance.

No other planners, members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose.

ACCREDITATION

In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME) and the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Pharmacy (CPE)

This knowledge-based activity provides 5.0 contact hours of continuing pharmacy education credit.

Physician (CME)

The University of Pittsburgh designates this live activity for a maximum of 5.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing (CNE)

The maximum number of hours awarded for this Continuing Nursing Education activity is 5.0 contact hours.

Physician Assistant (AAPA)

The University of Pittsburgh has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credits for activities planned in accordance with AAPA CME Criteria. This activity is designated for 5.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.  

Other healthcare professionals

Will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.

---

DISCLAIMER STATEMENT

The information presented at this activity represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the UPMC Center for Continuing Education in the Health Sciences, UPMC / University of Pittsburgh Medical Center or Affiliates and University of Pittsburgh School of Medicine.  Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

---

HOW TO OBTAIN CONTINUING EDUCATION

Continuing education can be claimed for the above learner groups. Learners must complete the full program (all modules, attain grades of 80% or higher on assessments, and participate in the live session) as well as submit the required information to the CE office (e.g. profile information and evaluations) prior to the deadline to receive continuing education credit. Partial credit will not be awarded.

Released: 8/13/2024
Expires: 08/12/2027

TARGET AUDIENCE

This course is designed for all healthcare professionals, including Nurses, Nurse Practitioners, Pharmacists, Physicians and Physician Assistants.

---

LEARNING MODULES

1. Precision medicine and PGx (2 units)
2. Foundations of PGx (3 units)
3. All about testing (3 units)
4. Principles of PGx decision making (5 units) 
5. Integrating PGx into your oncology practice (3 units)
   

---

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

Review foundational genomic concepts and nomenclature. Describe how PGx variation affects the pharmacokinetics and pharmacodynamics of chemotherapy agents. Order quality germline PGx testing when appropriate for oncology patients across their patient care journey. Explain the individual and societal risks and benefits of genetic testing in the healthcare setting. Identify germline gene-drug pairs and seminal clinical trial data with a high level of evidence in  oncology. Develop a stepwise decision-making process for the integration of PGx with clinical variables (e.g. phenoconversion) that known to impact PK/PD to make appropriate recommendations for oncology  patients and populations. Identify one's own role and that of other interprofessional team members to apply PGx into practice.

COURSE DURATION

Once enrolled, learners have 60 days to complete the program.

PLANNING COMMITTEE

	Philip Empey, PharmD, PhD,  FCCP Associate Professor, Pharmacy and Therapeutics, Associate Director, Institute of Precision Medicine; University of Pittsburgh School of Pharmacy (Course Director)
	James Coons, PharmD, FCCP, FACC, BCCP Professor, Pharmacy and Therapeutics, PGY2 Cardiology Residency Program Director, University of Pittsburgh School of Pharmacy
	Lucas Berenbrok, PharmD, MS, BCACP, TTS Associate Professor, Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy
	Deepak Voora, MD  Executive Director, VA National Pharmacogenomics Program VA Central Office, Washington, DC
	Jill Bates PharmD, MS, BCOP, DipACLM, FASHP Deputy Executive Director, VA National Pharmacogenomics Program VA Central Office, Washington, DC
	Trina Walker, DNP, APRN, FNP-C Assistant Professor, Nursing Creighton University
	Nguyen Park, MS, PA-C President and Founder, Society of PAs in Genetics/Genomics

---

PRENSENTERS (ALPHABETICAL ORDER)

	Lucas Berenbrok, PharmD, MS, BCACP, TTS Associate Professor, Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy
	Kelly Caudle, PharmD, PhD, BCPS, FCCP Associate Member, St. Jude Children's Research Hospital CPIC Director
	Philip Empey, PharmD, PhD,  FCCP Associate Professor, Pharmacy and Therapeutics, Associate Director, Institute of Precision Medicine; University of Pittsburgh School of Pharmacy
	Mylynda Massart, MD, PhD Associate Professor, Department of Family Medicine Primary Care Precision Medicine University of Pittsburgh
	Lisa Parker, PhD Director, Center for Bioethics and Health Law University of Pittsburgh
	Katherine Robinson, PharmD, MS, BCPS Clinical Pharmacogenomics Pharmacist University of Pittsburgh School of Pharmacy
	Robert Schuck, PharmD, PhD Deputy Director, Division of Translational and Precision Medicine Office of Clinical Pharmacology Center for Drug Evaluation and Research US Food and Drug Administration
	Michelle Whirl-Carrillo, PhD Principal Investigator and Director, PharmGKB Department of Biomedical Data Science Stanford University

---

CONFLICT OF INTEREST

Dr. Coons discloses that he receives grant/research support from Heart Rhythm Society, and Pfizer-Bristol Myers Squibb Alliance. He is a consultant for Merck and Pfizer-Bristol Myers Squibb Alliance.

No other planners, members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose.

ACCREDITATION

In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME) and the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Pharmacy (CPE)

This knowledge-based activity provides 5.0 contact hours of continuing pharmacy education credit.

Physician (CME)

The University of Pittsburgh designates this live activity for a maximum of 5.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing (CNE)

The maximum number of hours awarded for this Continuing Nursing Education activity is 5.0 contact hours.

Physician Assistant (AAPA)

The University of Pittsburgh has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credits for activities planned in accordance with AAPA CME Criteria. This activity is designated for 5.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.  

Other healthcare professionals

Will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.

---

DISCLAIMER STATEMENT

The information presented at this activity represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the UPMC Center for Continuing Education in the Health Sciences, UPMC / University of Pittsburgh Medical Center or Affiliates and University of Pittsburgh School of Medicine.  Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

---

HOW TO OBTAIN CONTINUING EDUCATION

Continuing education can be claimed for the above learner groups. Learners must complete the full program (all modules, attain grades of 80% or higher on assessments, and participate in the live session) as well as submit the required information to the CE office (e.g. profile information and evaluations) prior to the deadline to receive continuing education credit. Partial credit will not be awarded.

Released: 8/13/2024
Expires: 08/12/2027

TARGET AUDIENCE

This course is designed for all healthcare professionals, including Nurses, Nurse Practitioners, Pharmacists, Physicians and Physician Assistants.

---

LEARNING MODULES

1. Precision medicine and PGx (2 units)
2. Foundations of PGx (3 units)
3. All about testing (3 units)
4. Principles of PGx decision making (5 units) 
5. Integrating PGx into your mental health practice (3 units)
   

---

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

Review foundational genomic concepts and nomenclature. Describe how PGx variation affects the pharmacokinetics and pharmacodynamics of psychotropic medications. Order quality PGx testing when appropriate for mental health patients across their patient care journey. Explain the individual and societal risks and benefits of genetic testing in the healthcare setting. Identify gene-drug pairs and seminal clinical trial data with a high level of evidence in mental health. Develop a stepwise decision-making process for the integration of PGx with clinical variables (e.g. phenoconversion) that known to impact PK/PD to make appropriate recommendations for mental health patients and populations. Identify one's own role and that of other interprofessional team members to apply PGx into practice.

COURSE DURATION

Once enrolled, learners have 60 days to complete the program.

PLANNING COMMITTEE

	Philip Empey, PharmD, PhD,  FCCP Associate Professor, Pharmacy and Therapeutics, Associate Director, Institute of Precision Medicine; University of Pittsburgh School of Pharmacy (Course Director)
	James Coons, PharmD, FCCP, FACC, BCCP Professor, Pharmacy and Therapeutics, PGY2 Cardiology Residency Program Director, University of Pittsburgh School of Pharmacy
	Lucas Berenbrok, PharmD, MS, BCACP, TTS Associate Professor, Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy
	Deepak Voora, MD  Executive Director, VA National Pharmacogenomics Program VA Central Office, Washington, DC
	Jill Bates PharmD, MS, BCOP, DipACLM, FASHP Deputy Executive Director, VA National Pharmacogenomics Program VA Central Office, Washington, DC
	Trina Walker, DNP, APRN, FNP-C Assistant Professor, Nursing Creighton University
	Nguyen Park, MS, PA-C President and Founder, Society of PAs in Genetics/Genomics

---

PRENSENTERS (ALPHABETICAL ORDER)

	Lucas Berenbrok, PharmD, MS, BCACP, TTS Associate Professor, Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy
	Kelly Caudle, PharmD, PhD, BCPS, FCCP Associate Member, St. Jude Children's Research Hospital CPIC Director
	Philip Empey, PharmD, PhD,  FCCP Associate Professor, Pharmacy and Therapeutics, Associate Director, Institute of Precision Medicine; University of Pittsburgh School of Pharmacy
	Mylynda Massart, MD, PhD Associate Professor, Department of Family Medicine Primary Care Precision Medicine University of Pittsburgh
	Lisa Parker, PhD Director, Center for Bioethics and Health Law University of Pittsburgh
	Robert Schuck, PharmD, PhD Deputy Director, Division of Translational and Precision Medicine Office of Clinical Pharmacology Center for Drug Evaluation and Research US Food and Drug Administration
	James Stevenson, PharmD, MS Assistant Professor, Departments of Medicine and Pharmacology & Molecular Sciences Johns Hopkins University School of Medicine
	Michelle Whirl-Carrillo, PhD Principal Investigator and Director, PharmGKB Department of Biomedical Data Science Stanford University

---

CONFLICT OF INTEREST

Dr. Coons discloses that he receives grant/research support from Heart Rhythm Society, and Pfizer-Bristol Myers Squibb Alliance. He is a consultant for Merck and Pfizer-Bristol Myers Squibb Alliance.

No other planners, members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose.

ACCREDITATION

In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME) and the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Pharmacy (CPE)

This knowledge-based activity provides 5.0 contact hours of continuing pharmacy education credit.

Physician (CME)

The University of Pittsburgh designates this live activity for a maximum of 5.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing (CNE)

The maximum number of hours awarded for this Continuing Nursing Education activity is 5.0 contact hours.

Physician Assistant (AAPA)

The University of Pittsburgh has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credits for activities planned in accordance with AAPA CME Criteria. This activity is designated for 5.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.  

Other healthcare professionals

Will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.

---

DISCLAIMER STATEMENT

The information presented at this activity represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the UPMC Center for Continuing Education in the Health Sciences, UPMC / University of Pittsburgh Medical Center or Affiliates and University of Pittsburgh School of Medicine.  Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

---

HOW TO OBTAIN CONTINUING EDUCATION

Continuing education can be claimed for the above learner groups. Learners must complete the full program (all modules, attain grades of 80% or higher on assessments, and participate in the live session) as well as submit the required information to the CE office (e.g. profile information and evaluations) prior to the deadline to receive continuing education credit. Partial credit will not be awarded.

Released: 8/13/2024
Expires: 08/12/2027

TARGET AUDIENCE

This course is designed for all healthcare professionals, including Nurses, Nurse Practitioners, Pharmacists, Physicians and Physician Assistants.

---

LEARNING MODULES

1. Precision medicine and PGx (2 units)
2. Foundations of PGx (3 units)
3. All about testing (3 units)
4. Principles of PGx decision making (5 units) 
5. Integrating PGx into your primary care practice (8 units)
   

---

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

Review foundational genomic concepts and nomenclature. Describe how PGx variation affects the pharmacokinetics and pharmacodynamics of medications commonly prescribed in primary care settings. Order quality PGx testing when appropriate for cardiology patients across their patient care journey. Explain the individual and societal risks and benefits of genetic testing in the healthcare setting. Identify gene-drug pairs and seminal clinical trial data with a high level of evidence. Develop a stepwise decision-making process for the integration of PGx with clinical variables (e.g. phenoconversion) that known to impact PK/PD to make appropriate recommendations for primary care patients and populations. Identify one's own role and that of other interprofessional team members to apply PGx into practice.

COURSE DURATION

Once enrolled, learners have 60 days to complete the program.

PLANNING COMMITTEE

	Philip Empey, PharmD, PhD,  FCCP Associate Professor, Pharmacy and Therapeutics, Associate Director, Institute of Precision Medicine; University of Pittsburgh School of Pharmacy (Course Director)
	James Coons, PharmD, FCCP, FACC, BCCP Professor, Pharmacy and Therapeutics, PGY2 Cardiology Residency Program Director, University of Pittsburgh School of Pharmacy
	Lucas Berenbrok, PharmD, MS, BCACP, TTS Associate Professor, Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy
	Deepak Voora, MD  Executive Director, VA National Pharmacogenomics Program VA Central Office, Washington, DC
	Jill Bates PharmD, MS, BCOP, DipACLM, FASHP Deputy Executive Director, VA National Pharmacogenomics Program VA Central Office, Washington, DC
	Trina Walker, DNP, APRN, FNP-C Assistant Professor, Nursing Creighton University
	Nguyen Park, MS, PA-C President and Founder, Society of PAs in Genetics/Genomics

---

PRESENTERS (ALPHABETICAL ORDER)

	Lucas Berenbrok, PharmD, MS, BCACP, TTS Associate Professor, Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy
	Kelly Caudle, PharmD, PhD, BCPS, FCCP Associate Member, St. Jude Children's Research Hospital CPIC Director
	James Coons, PharmD, FCCP, FACC, BCCP Professor, Pharmacy and Therapeutics, PGY2 Cardiology Residency Program Director, University of Pittsburgh School of Pharmacy
	Philip Empey, PharmD, PhD,  FCCP Associate Professor, Pharmacy and Therapeutics, Associate Director, Institute of Precision Medicine; University of Pittsburgh School of Pharmacy
	Mylynda Massart, MD, PhD Associate Professor, Department of Family Medicine Primary Care Precision Medicine University of Pittsburgh
	Lisa Parker, PhD Director, Center for Bioethics and Health Law University of Pittsburgh
	Robert Schuck, PharmD, PhD Deputy Director, Division of Translational and Precision Medicine Office of Clinical Pharmacology Center for Drug Evaluation and Research US Food and Drug Administration
	D. Max Smith, PharmD, BCPS Clinical Pharmacogenomic Specialist, MedStar Health Assistant Professor, Georgetown University Medical Center
	Michelle Whirl-Carrillo, PhD Principal Investigator and Director, PharmGKB Department of Biomedical Data Science Stanford University

---

CONFLICT OF INTEREST

Dr. Coons discloses that he receives grant/research support from Heart Rhythm Society, and Pfizer-Bristol Myers Squibb Alliance. He is a consultant for Merck and Pfizer-Bristol Myers Squibb Alliance.

No other planners, members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose.

ACCREDITATION

In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME) and the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Pharmacy (CPE)

This knowledge-based activity provides 5.0 contact hours of continuing pharmacy education credit.

Physician (CME)

The University of Pittsburgh designates this live activity for a maximum of 5.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing (CNE)

The maximum number of hours awarded for this Continuing Nursing Education activity is 5.0 contact hours.

Physician Assistant (AAPA)

The University of Pittsburgh has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credits for activities planned in accordance with AAPA CME Criteria. This activity is designated for 5.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.  

Other healthcare professionals

Will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.

---

DISCLAIMER STATEMENT

The information presented at this activity represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the UPMC Center for Continuing Education in the Health Sciences, UPMC / University of Pittsburgh Medical Center or Affiliates and University of Pittsburgh School of Medicine.  Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

---

HOW TO OBTAIN CONTINUING EDUCATION

Continuing education can be claimed for the above learner groups. Learners must complete the full program (all modules, attain grades of 80% or higher on assessments, and participate in the live session) as well as submit the required information to the CE office (e.g. profile information and evaluations) prior to the deadline to receive continuing education credit. Partial credit will not be awarded.

Released: 8/13/2024
Expires: 08/12/2027

Test2Learn^TM is an award-winning training approach where you can work with real genetic data to learn pharmacogenomics. You can experience personal genomics testing just like your patients or work with anonymous data.  Interactive exercises and real world cases increase the fidelity of education and make training fun.  Learn all about our learning outcomes by clicking on the logo to the left. 

COURSE DIRECTOR

	Philip Empey, PharmD, PhD,  FCCP Associate Professor, Pharmacy and Therapeutics, Associate Director, Institute of Precision Medicine; University of Pittsburgh School of Pharmacy
	James Coons, PharmD, FCCP, FACC, BCCP Professor, Pharmacy and Therapeutics, PGY2 Cardiology Residency Program Director, University of Pittsburgh School of Pharmacy
	Lucas Berenbrok, PharmD, MS, BCACP, TTS Associate Professor, Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy
	Ashley Stewart, EdD, MA Instructional Designer, University of Pittsburgh School of Pharmacy
	Deepak Voora, MD  Executive Director, VA National Pharmacogenomics Program VA Central Office, Washington, DC
	Jill Bates PharmD, MS, BCOP, DipACLM, FASHP Deputy Executive Director, VA National Pharmacogenomics Program VA Central Office, Washington, DC
	Trina Walker, DNP, APRN, FNP-C Assistant Professor, Nursing Creighton University
	Nguyen Park, MS, PA-C President and Founder, Society of PAs in Genetics/Genomics

---

CONFLICT OF INTEREST

No members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients to disclose.

SELF-PACED, ONLINE STUDY

• To be completed in advance of the live program date.
  
  

---

FACULTY-LED, LIVE PROGRAM

Live portion of this program will be led by:
- Rebecca Graham, Sarai Ibrahim, and Jenna Carmichael

Day	Time
April 17, 2025	12 pm - 4 pm

(All times eastern and conducted over Microsoft Teams)

TARGET AUDIENCE

All healthcare professionals

---

LEARNING MODULES

Self-paced, online study Precision medicine and PGx (2 units) Foundations of PGx (4 units) PGx testing (3 units) PGx decision making (6 units)  PGx in clinical practice (7 units) Keys to successful implementation (3 units)

Live session Variation: One size does not fit all Using of trustworthy online information  How does a lab assign diplotypes Phenotypes to recommendations Decision making in practice: working through complex cases Developing PGx patient care plans Advancing your successful implementation and Wrap Up

---

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

Foundational Genetics Concepts (FG)

Explain basic genetics concepts using appropriate nomenclature. Recognize the combined impact of genetic, behavioral, social, and environmental factors in the manifestation of disease and drug response. Identify drug- and disease-associated genetic variations that facilitate development of prevention, diagnostic, and treatment strategies. Differentiate between the clinical diagnosis of disease informed by genetics and the identification of genetic predisposition to disease. Assess differences in genetic testing technologies, including sequencing and genotyping. Recognize the legal protections against discrimination based on genetic test results.

Clinical PGx (CP)

Identify pharmacogenomic test results that are relevant to a patient’s care. Interpret pharmacogenomic test results, including translating genotype to phenotype to drug therapy recommendation.  Determine the impact of genetic variation on pharmacokinetics and/or pharmacodynamics.  Identify medication-related problems that may be related to genetic variability, even when a pharmacogenomic test has not been done. Recognize disease implications of pharmacogenomic test results and refer the patient to a genetics-trained healthcare provider when necessary. Use family history to assess predisposition to disease and drug response.  Assess the quality and source of existing pharmacogenomic test results. Distinguish between actionable and non-actionable pharmacogenomic test results using high-quality, evidence-based pharmacogenomics databases and clinical guidelines.  Integrate pharmacogenomic test results with other clinical variables to optimize medication therapy. Recommend pharmacogenomic testing when appropriate. Consider the cost, cost-effectiveness, and reimbursement issues relevant to pharmacogenomic tests and services. Implement a pharmacogenomics-guided care plan in collaboration with the patient, caregivers, and other health professionals. Document pharmacogenomic test results in the electronic health record. Follow-up and monitor a pharmacogenomics-guided care plan. Collaborate as a member of an interprofessional clinical pharmacogenomics team. Identify patient populations that may be most likely to benefit from pharmacogenomic testing.  Identify genetic variations that predispose patients to adverse drug reactions and modify therapy accordingly to mitigate the risk.  Recognize the differences in pharmacogenomic allele frequencies among ancestry groups to guide appropriate test selection and maximize the appropriate use of medications in a population. Educate patients and professional colleagues on the benefits and limitations of pharmacogenomics to optimize drug therapy. Use a culturally-sensitive approach that considers potential ethical concerns when counseling patients about pharmacogenomic test results.  Use evidence-based resources and pharmacogenomics information to advance patient care. Oversee clinical pharmacogenomics operations. Fulfill a medication order considering the clinical implications of pharmacogenomics. Create a written plan for continuous professional development in clinical pharmacogenomics.

---

DISCLAIMER STATEMENT

The information presented at this activity represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the UPMC Center for Continuing Education in the Health Sciences, UPMC / University of Pittsburgh Medical Center or Affiliates and University of Pittsburgh School of Medicine.  Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

ACCREDITATION

In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME) and the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Pharmacy (CPE)

This knowledge-based activity provides 20.0 contact hours of continuing pharmacy education credit.

Physician (CME)

The University of Pittsburgh designates this live activity for a maximum of 20.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing (CNE)

The maximum number of hours awarded for this Continuing Nursing Education activity is 20.0 contact hours.

Physician Assistant (AAPA)

The University of Pittsburgh has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credits for activities planned in accordance with AAPA CME Criteria. This activity is designated for 20.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.  

Other healthcare professionals

Will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.

---

HOW TO OBTAIN CONTINUING EDUCATION

Continuing education can be claimed for the above learner groups. Learners must complete the full program (all modules, attain grades of 80% or higher on assessments, and participate in the live session) as well as submit the required information to the CE office (e.g. profile information and evaluations) prior to the deadline to receive continuing education credit. Partial credit will not be awarded.

Test2Learn^TM is an award-winning training approach where you can work with real genetic data to learn pharmacogenomics. You can experience personal genomics testing just like your patients or work with anonymous data.  Interactive exercises and real world cases increase the fidelity of education and make training fun.  Learn all about our learning outcomes by clicking on the logo to the left. 

COURSE DIRECTOR

	Philip Empey, PharmD, PhD,  FCCP Associate Professor, Pharmacy and Therapeutics, Associate Director, Institute of Precision Medicine; University of Pittsburgh School of Pharmacy
	James Coons, PharmD, FCCP, FACC, BCCP Professor, Pharmacy and Therapeutics, PGY2 Cardiology Residency Program Director, University of Pittsburgh School of Pharmacy
	Lucas Berenbrok, PharmD, MS, BCACP, TTS Associate Professor, Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy
	Ashley Stewart, EdD, MA Instructional Designer, University of Pittsburgh School of Pharmacy
	Deepak Voora, MD  Executive Director, VA National Pharmacogenomics Program VA Central Office, Washington, DC
	Jill Bates PharmD, MS, BCOP, DipACLM, FASHP Deputy Executive Director, VA National Pharmacogenomics Program VA Central Office, Washington, DC
	Trina Walker, DNP, APRN, FNP-C Assistant Professor, Nursing Creighton University
	Nguyen Park, MS, PA-C President and Founder, Society of PAs in Genetics/Genomics

---

CONFLICT OF INTEREST

No members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients to disclose.

SELF-PACED, ONLINE STUDY

• To be completed in advance of the live program date.
  
  

---

FACULTY-LED, LIVE PROGRAM

Live portion of this program will be led by:
- Rebecca Graham, Sarai Ibrahim, and Jenna Carmichael

Day	Time
April 30, 2025	12 pm - 4 pm HST

(All times HST and conducted over Microsoft Teams)

TARGET AUDIENCE

All healthcare professionals

---

LEARNING MODULES

Self-paced, online study Precision medicine and PGx (2 units) Foundations of PGx (4 units) PGx testing (3 units) PGx decision making (6 units)  PGx in clinical practice (7 units) Keys to successful implementation (3 units)

Live session Variation: One size does not fit all Using of trustworthy online information  How does a lab assign diplotypes Phenotypes to recommendations Decision making in practice: working through complex cases Developing PGx patient care plans Advancing your successful implementation and Wrap Up

---

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

Foundational Genetics Concepts (FG)

Explain basic genetics concepts using appropriate nomenclature. Recognize the combined impact of genetic, behavioral, social, and environmental factors in the manifestation of disease and drug response. Identify drug- and disease-associated genetic variations that facilitate development of prevention, diagnostic, and treatment strategies. Differentiate between the clinical diagnosis of disease informed by genetics and the identification of genetic predisposition to disease. Assess differences in genetic testing technologies, including sequencing and genotyping. Recognize the legal protections against discrimination based on genetic test results.

Clinical PGx (CP)

Identify pharmacogenomic test results that are relevant to a patient’s care. Interpret pharmacogenomic test results, including translating genotype to phenotype to drug therapy recommendation.  Determine the impact of genetic variation on pharmacokinetics and/or pharmacodynamics.  Identify medication-related problems that may be related to genetic variability, even when a pharmacogenomic test has not been done. Recognize disease implications of pharmacogenomic test results and refer the patient to a genetics-trained healthcare provider when necessary. Use family history to assess predisposition to disease and drug response.  Assess the quality and source of existing pharmacogenomic test results. Distinguish between actionable and non-actionable pharmacogenomic test results using high-quality, evidence-based pharmacogenomics databases and clinical guidelines.  Integrate pharmacogenomic test results with other clinical variables to optimize medication therapy. Recommend pharmacogenomic testing when appropriate. Consider the cost, cost-effectiveness, and reimbursement issues relevant to pharmacogenomic tests and services. Implement a pharmacogenomics-guided care plan in collaboration with the patient, caregivers, and other health professionals. Document pharmacogenomic test results in the electronic health record. Follow-up and monitor a pharmacogenomics-guided care plan. Collaborate as a member of an interprofessional clinical pharmacogenomics team. Identify patient populations that may be most likely to benefit from pharmacogenomic testing.  Identify genetic variations that predispose patients to adverse drug reactions and modify therapy accordingly to mitigate the risk.  Recognize the differences in pharmacogenomic allele frequencies among ancestry groups to guide appropriate test selection and maximize the appropriate use of medications in a population. Educate patients and professional colleagues on the benefits and limitations of pharmacogenomics to optimize drug therapy. Use a culturally-sensitive approach that considers potential ethical concerns when counseling patients about pharmacogenomic test results.  Use evidence-based resources and pharmacogenomics information to advance patient care. Oversee clinical pharmacogenomics operations. Fulfill a medication order considering the clinical implications of pharmacogenomics. Create a written plan for continuous professional development in clinical pharmacogenomics.

---

DISCLAIMER STATEMENT

The information presented at this activity represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the UPMC Center for Continuing Education in the Health Sciences, UPMC / University of Pittsburgh Medical Center or Affiliates and University of Pittsburgh School of Medicine.  Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

ACCREDITATION

In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME) and the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Pharmacy (CPE)

This knowledge-based activity provides 20.0 contact hours of continuing pharmacy education credit.

Physician (CME)

The University of Pittsburgh designates this live activity for a maximum of 20.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing (CNE)

The maximum number of hours awarded for this Continuing Nursing Education activity is 20.0 contact hours.

Physician Assistant (AAPA)

The University of Pittsburgh has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credits for activities planned in accordance with AAPA CME Criteria. This activity is designated for 20.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.  

Other healthcare professionals

Will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.

---

HOW TO OBTAIN CONTINUING EDUCATION

Continuing education can be claimed for the above learner groups. Learners must complete the full program (all modules, attain grades of 80% or higher on assessments, and participate in the live session) as well as submit the required information to the CE office (e.g. profile information and evaluations) prior to the deadline to receive continuing education credit. Partial credit will not be awarded.

Planning Committee for the ISCC-PEG Pharmacogenomics Learning Series:

• Philip Empey, PharmD, PhD, FCCP (University of Pittsburgh School of Pharmacy)
• Andrew Monte, MD, PhD (University of Colorado)
  
• Trina Walker, DNP, APRN, FNP-C (Creighton University)
• Nguyen Park, MS, PA-C (National Human Genome Research Institute)
• Jeneva Gularte-Rinaldo, PhD, RN (Samuel Merritt University)

Course Director

Spoorthy Reddy University of Colorado

Additional Content Reviewers

• Christina Aquilante, PharmD, Director of Pharmacogenomics for the Colorado Center for Personalized Medicine; Professor, Department of Pharmaceutical Sciences; University of Colorado
• Kathy Giacomini, PhD, Dean and Professor, School of Pharmacy; Co-Director UCSF-Stanford Center of Excellence in Regulatory Sciences and Innovation; University of California, San Francisco 
  

TARGET AUDIENCE

All healthcare professionals

---

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

• Review the nomenclature for PGx
  
• Review available evidence sources for pharmacogenomic recommendations. 
• Describe how Clinical Pharmacogenetic Implementation Consortium (CPIC) guidelines are developed, the components of a CPIC guideline and how CPIC guidelines can be used by clinicians to make specific prescribing decisions for patient care. 
• Retrieve the levels of evidence for gene/drug pairs.
• Integrate information from US Food and Drug Administration (FDA), CPIC, and PharmGKB into pharmacogenomic clinical decision making.

Planning Committee for the ISCC-PEG Pharmacogenomics Learning Series:

• Philip Empey, PharmD, PhD, FCCP (University of Pittsburgh School of Pharmacy)
• Andrew Monte, MD, PhD (University of Colorado)
  
• Trina Walker, DNP, APRN, FNP-C (Creighton University)
• Nguyen Park, MS, PA-C (National Human Genome Research Institute)
• Jeneva Gularte-Rinaldo, PhD, RN (Samuel Merritt University)

Course Directors

	Philip Empey, PharmD, PhD Associate Professor and Director, Pharmacogenomics Center of Excellence University of Pittsburgh School of Pharmacy
	Benjamin Brown American Society of Pharmacovigilance

Additional Content Reviewers

• Kelly Caudle, PharmD, PhD, Director, Clinical Pharmacogenetics Implementation Consortium
• Wendy Rubinstein, MD, PhD, Director, Personalized Medicine, Food & Drug Administration (Questions 1 and 3 only).  The review does not constitute an endorsement by FDA or any of its employees
  

TARGET AUDIENCE

All healthcare professionals

---

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

• Review available evidence sources for pharmacogenomic recommendations. 
  
• Describe the components of a CPIC guideline and how CPIC guidelines can be used by clinicians to make specific prescribing decisions for patient care. 
• Explain how evidence-based guidelines are developed by CPIC.
• Retrieve the levels of evidence for gene/drug pairs.
• Integrate information from FDA, CPIC, and PharmGKB into pharmacogenomic clinical decision making.
  

Planning Committee for the ISCC-PEG Pharmacogenomics Learning Series:

• Philip Empey, PharmD, PhD, FCCP (University of Pittsburgh School of Pharmacy)
• Andrew Monte, MD, PhD (University of Colorado)
  
• Trina Walker, DNP, APRN, FNP-C (Creighton University)
• Nguyen Park, MS, PA-C (National Human Genome Research Institute)
• Jeneva Gularte-Rinaldo, PhD, RN (Samuel Merritt University)

Course Directors

	Otito Frances Iwuchukwu, PhD, MA Associate Professor Fairleigh Dickinson University
	Jenny Nguyen, PharmD, APh, BCPS Clinical Pharmacogenomics Specialist Children's Hospital Los Angeles

Additional Content Reviewers

• Natasha Petry, PharmD, BCACP, Associate Professor, North Dakota State University and Sanford Health Imagenetics
• Vivian K. Kawai MD, MPH, Director of Pharmacogenomics, Vanderbilt University School of Medicine
  

TARGET AUDIENCE

All healthcare professionals

---

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

• Describe the components and practical aspects of standard pharmacogenomics implementation.
  
• Identify the roles of various healthcare professionals in implementation teams.
• Evaluate curated examples of successful implementation programs in different practice settings.
• Apply model principles of pharmacogenomics implementation using a familiar and readily implementable gene-drug or gene-disease pair case example for a clinical practice (or system).

Planning Committee for the ISCC-PEG Pharmacogenomics Learning Series:

• Philip Empey, PharmD, PhD, FCCP (University of Pittsburgh School of Pharmacy)
• Andrew Monte, MD, PhD (University of Colorado)
  
• Trina Walker, DNP, APRN, FNP-C (Creighton University)
• Nguyen Park, MS, PA-C (National Human Genome Research Institute)
• Jeneva Gularte-Rinaldo, PhD, RN (Samuel Merritt University)

Course Directors

Roseann S. Donnelly (Gammal), PharmD, BCPS   Associate Professor  Massachusetts College of Pharmacy and Health Sciences

Additional Content Reviewers

• Cyrine-Eliana Haidar, PharmD, BCPS, BCOP, FASHP, Clinical Pharmacogenetics Coordinator, St. Jude Children’s Research Hospital
• David Kisor, PharmD, FCP, Professor of Pharmaceutical Sciences and Pharmacogenomics, Manchester University
  

TARGET AUDIENCE

All healthcare professionals

---

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

• Differentiate between the delivery models for pharmacogenomic testing.
  
• Identify the benefits and limitations of direct-to-consumer (DTC) pharmacogenomic testing.
• Interpret DTC pharmacogenomic test results.
• Evaluate the clinical actionability of genetic variants detected by a DTC pharmacogenomic test using evidence-based resources.
• Determine when confirmatory clinical testing is needed when faced with DTC pharmacogenomic test results.
• Explain why confirmatory clinical pharmacogenomic test results may differ from direct-to-consumer pharmacogenomic test results for the same patient. 
• Discuss issues related to documenting DTC pharmacogenomic test results in the electronic health record. 

Planning Committee for the ISCC-PEG Pharmacogenomics Learning Series:

• Philip Empey, PharmD, PhD, FCCP (University of Pittsburgh School of Pharmacy)
• Andrew Monte, MD, PhD (University of Colorado)
  
• Trina Walker, DNP, APRN, FNP-C (Creighton University)
• Nguyen Park, MS, PA-C (National Human Genome Research Institute)
• Jeneva Gularte-Rinaldo, PhD, RN (Samuel Merritt University)

Course Directors

Karen Niemchick, PhD, MHS  Grand Valley State University

Additional Content Reviewers

• Joshua Peterson, MD, Vanderbilt University 
• Caleb Bupp, MD, Spectrum Health
  

TARGET AUDIENCE

All healthcare professionals

---

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

• Understand a basic cost analysis
• Compare benefits of genetic testing with traditional treatment. 
• Gain experience in accessing genetic test information.
  

Planning Committee for the ISCC-PEG Pharmacogenomics Learning Series:

• Philip Empey, PharmD, PhD, FCCP (University of Pittsburgh School of Pharmacy)
• Andrew Monte, MD, PhD (University of Colorado)
  
• Trina Walker, DNP, APRN, FNP-C (Creighton University)
• Nguyen Park, MS, PA-C (National Human Genome Research Institute)
• Jeneva Gularte-Rinaldo, PhD, RN (Samuel Merritt University)

Course Directors

	Sara Rogers, PharmD, BCPS   American Society of Pharmacovigilance Texas A&M University
	Benjamin Brown   American Society of Pharmacovigilance
	Christine Formea, PharmD, BCPS, FCCP, FASHP Children’s Hospital Colorado

Additional Content Reviewers

• Jai Patel, PharmD, BCOP, CPP, Levine Cancer Institute, Atrium Health
• Chet Robson, DO, MHCDS, FAAFP, Jasper Health
  

TARGET AUDIENCE

All healthcare professionals

---

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

• Define relevant reimbursement related terminology
• Review key components of payer coverage guidance for pharmacogenomics testing 
• Describe technical requirements for test reports 
• Understand special documentation requirements to show medical necessity